Seeking Alpha

Acusphere, Inc. (ACUS)

()

Instablog posts on ACUS

  • FDA Calendar Update: Acusphere, Cephalon by Mike Havrilla
    Below is a summary of updates to the BioMedReports.com database of over 200 entries included in the FDA and Clinical Trial Calendars. The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA decision... More »
    May 24, 2009 • ACUS, CEPH
  • Business Conferences - ACUS, HEB by Michael Catalin Vlaicu
    Today I have some exciting news to share with you all. Due to the influx of emails I have been receiving lately on inquiries regarding the latest FDA deadlines on (Public, AMEX:HEB) and (Public, OTC:ACUS), StocksHaven Investments alongside BioMedReports.com will be hosting video and phone... More »
    May 12, 2009 • ACUS, HEB
  • FDA Watchlist - ACUS by Michael Catalin Vlaicu
    Acusphere, Inc.(Public, OTC:ACUS) It is important to note that as with all FDA pending approvals, there is a tremendous amount of uncertainty. However, just remember that amongst uncertainty lies opportunity! That being said, continuing with the FDA journey to riches I have chosen ACUS as my... More »
    May 9, 2009 • ACUS
  • An Extreme FDA Trade that Paid: Vanda Pharma (NASDAQ:VNDA) by Mike Havrilla
    Shares of Vanda Pharma (NASDAQ:VNDA) soared by nearly nine-fold in after-hours trading Wednesday evening as Fanapt (iloperidone) was approved by the FDA for the acute treatment of adult patients with schizophrenia. The approval was supported by two placebo-controlled Phase 3 clinical studies... More »
    May 6, 2009 • VNDA, ADLS, TSPT

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.